Literature DB >> 29785507

Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease.

Robert L Mango1, Eric L Matteson1,2, Cynthia S Crowson1,2, Jay H Ryu3, Ashima Makol4,5.   

Abstract

PURPOSE: The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis.
METHODS: The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded. The performance of the models was assessed using standardized mortality ratios (SMR) of observed versus predicted outcomes for calibration and concordance (c)-statistics for discrimination.
RESULTS: SSc-ILD patients with usual interstitial pneumonia (31, 17%) had a higher mortality than those with non-specific interstitial pneumonia (147, 83%) (hazard ratio 2.27; 95%CI 1.03-4.97). All 3 models had comparable discrimination (c = 0.72, 0.72, and 0.71, respectively). Regarding calibration, the ILD-GAP model underestimated mortality (SMR 1.50; 95%CI 1.05-2.14). Calibration was acceptable for SADL (SMR 1.00; 95%CI 0.70-1.44) and GAP (SMR 0.90; 95%CI 0.63-1.29). The SADL model underestimated mortality in Stage I ILD.
CONCLUSIONS: The ILD-GAP model underestimated mortality, and the SADL model underestimated mortality in certain subgroups. However, the GAP model performed well in this cohort, providing the best prognostic information for SSc-ILD.

Entities:  

Keywords:  Interstitial lung disease; Mortality modeling; Non-specific interstitial pneumonia; Systemic sclerosis; Usual interstitial pneumonia

Mesh:

Year:  2018        PMID: 29785507     DOI: 10.1007/s00408-018-0126-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  31 in total

Review 1.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Authors:  Dinesh Khanna; Shikha Mittoo; Rohit Aggarwal; Susanna M Proudman; Nicola Dalbeth; Eric L Matteson; Kevin Brown; Kevin Flaherty; Athol U Wells; James R Seibold; Vibeke Strand
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

2.  6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Jonathan A Leff; Paul W Noble; Steven A Sahn; Dominique Valeyre; Derek Weycker; Talmadge E King
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

3.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

4.  Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Authors:  Nicole S Goh; Rachel K Hoyles; Christopher P Denton; David M Hansell; Elisabetta A Renzoni; Toby M Maher; Andrew G Nicholson; Athol U Wells
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

5.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model.

Authors:  Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

6.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

Review 7.  Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.

Authors:  Muriel Elhai; Christophe Meune; Jérôme Avouac; André Kahan; Yannick Allanore
Journal:  Rheumatology (Oxford)       Date:  2011-09-07       Impact factor: 7.580

8.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

9.  Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Vincent Cottin; Kevin R Flaherty; Martin Kolb; Yoshikazu Inoue; Ganesh Raghu; Hiroyuki Taniguchi; David M Hansell; Andrew G Nicholson; Florence Le Maulf; Susanne Stowasser; Harold R Collard
Journal:  Respir Med       Date:  2014-04-29       Impact factor: 3.415

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

View more
  6 in total

1.  Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.

Authors:  David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

Review 2.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

3.  Prediction of long-term mortality by using machine learning models in Chinese patients with connective tissue disease-associated interstitial lung disease.

Authors:  Di Sun; Yu Wang; Qing Liu; Tingting Wang; Pengfei Li; Tianci Jiang; Lingling Dai; Liuqun Jia; Wenjing Zhao; Zhe Cheng
Journal:  Respir Res       Date:  2022-01-07

Review 4.  Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.

Authors:  Surabhi Agarwal Khanna; John W Nance; Sally A Suliman
Journal:  Curr Rheumatol Rep       Date:  2022-05-01       Impact factor: 4.686

5.  Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept.

Authors:  K Martini; B Baessler; M Bogowicz; C Blüthgen; M Mannil; S Tanadini-Lang; J Schniering; B Maurer; T Frauenfelder
Journal:  Eur Radiol       Date:  2020-10-06       Impact factor: 5.315

6.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.

Authors:  Ralf Ewert; Till Ittermann; Dirk Habedank; Matthias Held; Tobias J Lange; Michael Halank; Jörg Winkler; Sven Gläser; Horst Olschewski; Gabor Kovacs
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.